Reduction of phenylephrine drop size in infants achieves equal dilation with decreased systemic absorption.

We studied the effect of reducing eye drop size on the efficacy and systemic absorption of topical 2.5% phenylephrine hydrochloride in neonates and infants. Eleven neonates received an 8-microL drop volume in one eye and a 30-microL drop volume (commercial size) in the fellow eye. Mean pupillary dilation at 60 minutes was equivalent (4.86 mm vs 4.57 mm) for both eyes, respectively. The plasma phenylephrine level was determined for the two drop sizes in a second group of infants. Eight infants received an 8-microL drop volume in both eyes, while nine infants received a 30-microL drop volume in both eyes. The mean phenylephrine level at ten minutes was 0.9 ng/mL for the 8-microL drop group and 1.9 ng/mL for the 30 microL drop group. In neonates and infants, reducing the drop volume of topical phenylephrine may improve the risk-benefit ratio.

[1]  R. Brown,et al.  Improving the therapeutic index of topical phenylephrine by reducing drop volume. , 1987, Ophthalmology.

[2]  M. Kass,et al.  Compliance with topical pilocarpine treatment. , 1986, American journal of ophthalmology.

[3]  R. Schoenwald,et al.  Fluorometric determination of phenylephrine hydrochloride by liquid chromatography in human plasma. , 1985, Journal of pharmaceutical sciences.

[4]  P. Hyman,et al.  Effects of cyclopentolate eyedrops on gastric secretory function in pre-term infants. , 1985, Ophthalmology.

[5]  F. Fraunfelder,et al.  Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. , 1985, American journal of ophthalmology.

[6]  T. Zimmerman,et al.  Improving the therapeutic index of topically applied ocular drugs. , 1984, Archives of ophthalmology.

[7]  E. Palmer,et al.  Plasma timolol in glaucoma patients. , 1984, Ophthalmology.

[8]  J W Shell,et al.  Pharmacokinetics of topically applied ophthalmic drugs. , 1982, Survey of ophthalmology.

[9]  S. Isenberg,et al.  Systemic effects of mydriatics in low weight infants. , 1981, Journal of pediatric ophthalmology and strabismus.

[10]  L. Cabal,et al.  Increased blood pressure following pupillary dilation with 2.5% phenylephrine hydrochloride in preterm infants. , 1981, Pediatrics.

[11]  J. Calhoun,et al.  Development of monofixation syndrome in congenital esotropia. , 1981, Journal of pediatric ophthalmology and strabismus.

[12]  D. Maurice.  Factors influencing the penetration of topically applied drugs. , 1980, International ophthalmology clinics.

[13]  S. Mishima,et al.  Pharmacokinetics of instilled drugs in the human eye. , 1980, International ophthalmology clinics.

[14]  A. Caputo,et al.  Systemic response to mydriatic eyedrops in neonates: mydriatics in neonates. , 1978, Journal of pediatric ophthalmology and strabismus.

[15]  J. Robinson,et al.  Lacrimal and instilled fluid dynamics in rabbit eyes. , 1973, Journal of pharmaceutical sciences.

[16]  H. Keitel,et al.  SYSTEMIC HYPERTENSION FOLLOWING OCULAR ADMINISTRATION OF 10% PHENYLEPHRINE IN THE NEONATE , 1973, Pediatrics.

[17]  C. Bauer,et al.  Systemic cyclopentolate (Cyclogyl) toxicity in the newborn infant. , 1973, The Journal of pediatrics.

[18]  A SORSBY,et al.  The eye at birth: measurement of the principal diameters in forty-eight cadavers. , 1960, Journal of anatomy.